Search
forLearn
5 / 801 resultslearn Synergen Complex ®
learn TeraBond™ (Actera)
learn AminoMar™
learn oligopeptide-71
Research
5 / 36 resultsresearch Investigating the Genetic Association of Selected Candidate Loci with Alopecia Areata Susceptibility in Jordanian Patients
No significant genetic link to alopecia areata was found in the Jordanian group.
research Forensic DNA phenotyping: a review on SNP panels, genotyping techniques, and prediction models
Forensic DNA phenotyping faces challenges like inconsistent terms and limited genetic knowledge.
research Evaluation of Susceptibility Genes/Loci Associated with Male Androgenetic Alopecia (MAGA) for Female-Pattern Hair Loss in a Chinese Han Population and a Brief Literature Review
Male and female hair loss have different genetic causes.
research Evidence of increased DNA methylation of the androgen receptor gene in occipital hair follicles from men with androgenetic alopecia
Men with hair loss have more DNA changes in back-of-head hair follicles, possibly protecting them from thinning.
research Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss
Aromatase gene variation may increase female hair loss risk.
Community Join
5 / 1000+ resultscommunity I have heard that Amplifica - Scube3 initiate a human study for AGA, but I cannot find any information about it from clinictrial.gov. Amplifica did not state it is a phase 1 clinic trial or not, it says it is "The initiation of our first-in-human clinical study"
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
community Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community Calecim (PTT-6) Advanced Hair System with Topical Exosomes and Growth Factors for Hair Growth
Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.
community New company Amplifica gets $11.8 million in financing for development of its hair loss products. Dr. Maksim Plikus and William Rassman are co-founders.
New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.